The American Diabetes Association’s 86th Scientific Sessions wrapped up Monday in New Orleans, and the data coming out of the meeting is already reshaping expectations for obesity drugs. More than 12,000 researchers from over 115 countries gathered at the Ernest N. Morial Convention Center, and the pipeline delivered on its promise of landmark readouts. Eli Lilly’s triple-agonist retatrutide posted weight loss numbers that match bariatric surgery, Boehringer Ingelheim’s survodutide showed a strong effect on fatty liver disease, Pfizer’s monthly injectable berobenatide made its Phase 2b debut, and the amylin analog class made a credible comeback. For clinicians setting formulary expectations and patients watching the race, these results will drive coverage decisions for the next 18 months.
The conference covered more than 200 sessions across 25 topic areas. But the headline was unmistakably the parade of Phase 3 readouts for next-generation agents, each competing to define the post-semaglutide era. More than two in five American adults live with obesity, and the data shifted what’s considered possible with medication alone.
Retatrutide Weight Loss Reaches Bariatric Surgery Levels
Eli Lilly’s retatrutide TRIUMPH-1 trial delivered the most consequential data, presented Saturday and published simultaneously.
Lilly also presented data from the TRANSCEND-T2D-1 trial in type 2 diabetes, published in The Lancet. Retatrutide lowered HbA1c by up to 2.0% and reduced weight by up to 16.8% at 40 weeks. Results from nested basket trials covering knee osteoarthritis pain and obstructive sleep apnea extended the drug’s potential footprint.
Tolerability carries real caveats. Discontinuation rates due to adverse events climbed with dose: 4.1% at 4 mg, 6.9% at 9 mg, and 11.3% at 12 mg, versus 4.9% on placebo. Nausea affected 42.4% at the highest dose; vomiting, 25.3%; and dysesthesia, an abnormal skin sensation, reached 12.5% versus 0.9% on placebo. Session moderator Prof. Naveed Sattar of the University of Glasgow noted the data were exciting but cautioned that rapid weight reduction at scale may introduce risks not yet fully characterized.
Related: Bezos bets on brain-like startup for AI power fix
Why Adding Glucagon Broke the Ceiling
Retatrutide’s mechanism separates it from every prior drug in this class. Approved GLP-1 agents like semaglutide activate a single receptor; tirzepatide activates two — GLP-1 and GIP. Retatrutide adds a third: the glucagon receptor, making it the first triple agonist to reach Phase 3.
Each receptor contributes a distinct metabolic pathway. GLP-1 suppresses appetite and slows gastric emptying. GIP amplifies insulin response and may reduce nausea at higher doses. The glucagon receptor is where retatrutide departs: glucagon agonism normally raises blood glucose, but the insulinotropic effects of GLP-1 and GIP counterbalance that while preserving the glucagon receptor’s metabolic-rate-enhancing effects — increased thermogenesis and accelerated fat breakdown.
Preclinical research and Phase 2 data suggested this three-receptor balance would produce more weight loss than dual agonism, because resting metabolic rate would be raised rather than suppressed as weight falls.
No FDA submission for retatrutide has been filed as of today. Lilly has seven additional Phase 3 readouts expected before year’s end, including TRIUMPH-2 in obesity plus type 2 diabetes and TRIUMPH-3 in obesity plus established cardiovascular disease.
Survodutide Targets Liver Fat, Not Just Weight
Boehringer Ingelheim and Zealand Pharma delivered the full SYNCHRONIZE-1 results, with data appearing simultaneously in The New England Journal of Medicine. Survodutide, a glucagon/GLP-1 dual agonist, achieved up to 16.6% average weight loss after 76 weeks — broadly on par with semaglutide but below retatrutide’s numbers. Up to 85.1% of survodutide-treated patients lost at least 5% of body weight, versus 38.8% on placebo. Weight reduction was driven predominantly by fat tissue rather than lean mass, a key distinction for the field’s concern about muscle loss.
Survodutide drew the most attention from liver specialists in a body-composition sub-study and the SYNCHRONIZE-MASLD trial, published in Nature Medicine. The sub-study showed the drug reduced visceral fat by up to 34% at week 76. Liver fat, measured by MRI, fell by up to 63.1%. In SYNCHRONIZE-MASLD, which enrolled 218 adults with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), survodutide met both co-primary endpoints: up to 84.2% achieved at least 30% relative liver fat reduction, and liver fat normalization was reached by 6 in 10 treated participants at 48 weeks.
Related: Mac Studio M3 Ultra Resale Prices Spike to $25,000 – What’s Driving the Hype?
The glucagon mechanism drives this liver effect. Glucagon agonism acts directly on hepatocytes to reduce fat accumulation and is thought to resolve inflammation. Up to 75% of people with obesity develop MASLD, and roughly a third advance to more serious forms. With no widely used pharmacological standard of care for MASLD, survodutide’s liver profile creates a potential commercial niche independent of where it finishes on the obesity efficacy leaderboard.
Discontinuation data drew scrutiny. In SYNCHRONIZE-1, 19% of survodutide-treated patients discontinued due to gastrointestinal adverse events, versus 2.9% on placebo. Boehringer characterized the events as mild to moderate and concentrated during dose escalation; the company plans optimized dosing protocols.
Pfizer’s Monthly GLP-1: Albumin Binding Extends Half-Life
Pfizer used the meeting to debut berobenatide (PF-08653944), a potential first-in-class monthly GLP-1 receptor agonist acquired through its $10 billion purchase of Metsera. The molecular engineering behind the monthly dosing interval is not a reformulation of existing peptides; it is a structurally distinct design built around albumin binding.
Standard GLP-1 drugs are broken down by the body within about seven days. Berobenatide is engineered to bind tightly to albumin, the most abundant protein in blood plasma, through terminal lipidation. This attachment protects the molecule from enzymatic degradation and renal clearance, extending its half-life dramatically. The drug is also a “fully biased” GLP-1 agonist, meaning it preferentially activates cAMP signaling over the beta-arrestin pathway, which is thought to prolong efficacy and reduce receptor desensitization.
In VESPER-1, patients who escalated to 2.4 mg weekly berobenatide achieved non-placebo-adjusted weight loss of approximately 16% at week 32 with no plateau observed. VESPER-3, which tested the transition from weekly to monthly dosing, showed placebo-adjusted weight loss of up to 12.3% at 28 weeks on the 4.8 mg monthly dose. In VESPER-2, the type 2 diabetes cohort, the agent produced a 2.2% reduction in HbA1c versus 0.2% change on placebo at 28 weeks. Tolerability was favorable: low gastrointestinal adverse events and low discontinuation rates were reported even under rapid dose escalation.
Related: Apple joins China’s national subsidy program
Analysts struck a measured tone. The efficacy numbers from Phase 2b sit below current leaders — 12–16% non-placebo-adjusted at comparable durations versus retatrutide’s 28%+ and tirzepatide’s 20%+ at Phase 3 scale. The differentiating case for berobenatide rests primarily on dosing convenience: a once-monthly injection could improve real-world adherence for a condition that requires indefinite treatment. Pfizer plans 10 Phase 3 studies in 2026, including the VESPER-6 key trial for monthly maintenance dosing. The company has also indicated it intends to launch a direct-to-consumer cash-pay option at market entry.
Amylin Analogs and the GLP-1 Combination Pipeline
Away from the headline Phase 3 readouts, a quieter story developed around amylin analogs. Zealand Pharma and Roche presented Phase 2 data from the ZUPREME-1 trial of petrelintide, a once-weekly amylin analog. Participants achieved clinically meaningful weight reductions versus placebo over 42 weeks. The amylin pathway works through a distinct mechanism: it slows gastric emptying, suppresses postprandial glucagon, and acts on the area postrema to reduce food intake — complementary rather than overlapping with GLP-1 signaling. The clinical hypothesis is that combining amylin and GLP-1 pathways could achieve additive weight reduction while distributing the tolerability burden across mechanisms.
Ascletis Pharma presented Phase 2b data for ASC30, an oral GLP-1 receptor agonist tablet showing dose-dependent weight loss with a favorable gastrointestinal tolerability profile. The company plans to initiate global Phase 3 trials by the end of Q3 2026. The breadth of international submissions — from Chinese, Irish, and European companies alongside the major American and Danish players — showed how thoroughly the obesity drug race has become a global industrial competition.
ADA Standards and What the Data Mean for Coverage
Earlier in 2026, the ADA’s Obesity Association published the first dedicated pharmacologic treatment section of its Standards of Care in Overweight and Obesity. That document includes 34 new recommendations covering medication selection, goal setting, long-term management, and special populations. It is already being used by payers and health systems as an anchor for clinical appropriateness criteria.
For clinicians and coverage decision-makers, the 2026 ADA Scientific Sessions will be remembered as the meeting where the benchmarks for “effective” changed. Retatrutide’s surgery-level numbers demand a rethinking of what pharmacological treatment can achieve. Survodutide’s liver data open a second therapeutic front. Berobenatide’s monthly dosing, if it holds through Phase 3, addresses a real adherence gap. The harder question — which drugs survive to commercial practice at accessible prices — will play out over the next 18 months as FDA submissions accumulate and payers draw their formulary red lines. None of the drugs highlighted in New Orleans this week has received FDA approval. The data generated here are the evidence on which those decisions will rest.